Curis Lifesciences Limited IPO Details

SME

Curis Lifesciences IPO opens for subscription on 07 Nov 2025 and closes on 11 Nov 2025. The IPO will be listed on NSE with the tentative listing date set for 14 Nov 2025.

Curis Lifesciences IPO price band has been fixed at ₹120 – ₹128 per share.The face value is ₹10 per share with a lot size of 1000.

Curis Lifesciences IPO total issue size comprises 21,50,000 shares (aggregating up to ₹27.52 Cr.). This includes a fresh issue of 21,50,000 shares (aggregating up to ₹27.52 Cr.). Pre-issue shareholding stands at 59,34,434, which will increase to 80,84,434 post-issue.

Curis Lifesciences IPO carries a ₹6 (4.7%) GMP, reflecting investor sentiment.

Curis Lifesciences IPO Lot Size : Individual Minimum is 2 lots (2,000 shares) amounting to ₹256,000. Individual Maximum is 2 lots (2,000 shares) amounting to ₹256,000. SHNI Minimum is 3 lots (3,000 shares) amounting to ₹384,000. SHNI Maximum is 7 lots (7,000 shares) amounting to ₹896,000. BHNI Minimum is 8 lots (8,000 shares) amounting to ₹1,024,000.

The Lead Managers for Curis Lifesciences IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Swastika Investmart Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.

For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is RS Wealth Management Private Limited. You can analyze their track record by checking the Market Maker Performance Summary report.

For detailed information, Refer to the Curis Lifesciences Limited RHP.

Curis Lifesciences IPO Details

Open Date

07 Nov 2025

Close Date

11 Nov 2025

Listing Date

14 Nov 2025

Issue Price

₹120 - ₹128

Face Value

₹10 per share

Lot Size

1000

GMP

₹6 (4.7%)

Issue Type

IPO

Listing On

NSE

Type

Book Built Issue

Share holding pre issue

5934434

Share holding post issue

8084434

Total Issue Size

21,50,000 shares (aggregating up to ₹27.52 Cr.)

Fresh Issue

21,50,000 shares (aggregating up to ₹27.52 Cr.)

Offer for Sale

Curis Lifesciences IPO Dates

07 Nov 2025
Opening dateOPD
11 Nov 2025
Closing dateCOD
12 Nov 2025
Allotment Date BOA
13 Nov 2025
Initiation of RefundsIOR
13 Nov 2025
Credit of SharesCOS
14 Nov 2025
Listing dateLID

Curis Lifesciences IPO Lot Size

Application	Lots	Shares	Amount
Individual Minimum	2	2000	₹256,000
Individual Maximum	2	2000	₹256,000
SHNI Minimum	3	3000	₹384,000
SHNI Maximum	7	7000	₹896,000
BHNI Minimum	8	8000	₹1,024,000

Curis Lifesciences IPO Reservation

Promoter Holding

Pre Issue:92.68%

Post Issue:68.03%

Promoter Names:

Mr. Dharmesh Dashrathbhai Patel, Mr. Siddhant Jayantibhai Pawasia, Mr. Piyush Gordhanbhai Antala, Mr. Jaimik Mansukhbhai Patel

Documents

› Curis Lifesciences IPO DRHP

› Curis Lifesciences IPO RHP

Curis Lifesciences IPO Valuations

ROE:145.20%

ROCE:34.89%

DEBT/EQUITY:2.86

RONW:84.12%

PAT MARGIN:14.13%

Curis Lifesciences Financial Information

Period Ended	31 Dec 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	50.12	33.82	29.67	27.40
Total Income	36.91	35.89	36.39	23.76
Profit After Tax	5.30	5.03	1.85	0.49
EBITDA	8.89	8.41	3.25	3.58
Net Worth	15.53	5.97	0.95	0.90
Reserves and Surplus	9.59	5.47	0.45	-1.40
Total Borrowing	16.16	17.09	16.19	17.62
Amount in ₹ Crore

About Curis Lifesciences IPO

Established in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.

The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.

The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.

Curis Lifesciences specialises in the development, manufacturing, and distribution of a diverse range of pharmaceutical products, including:

General pharmaceutical tablets and capsules
Oral liquids
External preparations
Sterile ophthalmic ointments

The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.

The company offers various pharmaceutical formulations and products manufactured under contract.

They supply tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments.

As of June 30th, 2024, the company has 93 permanent employees.

Strength Of Curis Lifesciences IPO

Experienced Promoters and Management Team.
Wide range of Products.
Strategic Location of Manufacturing Facility.
Scalable Business Model.
Quality assurance.

Risk Of Curis Lifesciences IPO

Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
Our business operations are subject to fluctuations in raw material prices.
The company relies on a limited number of customers for its sales, and the loss of any major customer could adversely impact our revenue and profitability.
The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.
We depend on a limited number of States for a significant portion of our revenue from operations. The loss of any of our major customer in this States due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
Our Company is dependent on a few countries. Loss of any of these large countries may affect our business operations.
Our Company depends on some of our Products which contributes 100% of the total revenue of the company. The loss of any of this major Products due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
The Statutory Auditor and the Peer Review Auditor of the company are not same.
There are certain discrepancies/errors which have occurred in some of our corporate secretarial records relating to forms filed with the RoC and other provisions of Companies Act, 2013. Any penalty or action taken by any regulatory authorities in future.

Objectives Curis Lifesciences IPO

1. Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities

2. Capital Expenditure towards Construction of a Storage Facility

3. Pre-payment/Repayment of outstanding Secured Loans

4. Product Registrations in other countries

5. Funding our Working Capital Requirements

6. General Corporate Purposes

Company Contact Details

Curis Lifesciences Ltd.
PF-23, GIDC Sanand - II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/